A New Hepatitis C Medicine: Faldaprevir
Share
Follow Us
The Editors at Hepatitis Central
January 28, 2014
Learn about the trial results for faldaprevir, a once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor.
Faldaprevir an Anticipated Addition to HCV Armamentarium
ISSUE: JANUARY 2014 | VOLUME: 1
by David Wild
Treatment with faldaprevir, a once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) led to a sustained virologic response (SVR) at week 12 in 80% of patients with HCV genotype 1, findings from a large, randomized placebo-controlled trial of the drug revealed.
Continue reading this entire article:
http://www.idse.net/ViewArticle.aspx?d=Hepatitis&d_id=213&i=January+2014&i_id=1027&a_id=25823
